Interleukin / Interleukin Antagonists Drugs Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Interleukin (IL-5) / Interleukin (IL-5R) Antagonists Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2024

Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. Through binding to the interleukin-5 receptor, interleukin 5 stimulates B cell growth and increases immunoglobulin secretion - primarily IgA and it is also a key mediator in eosinophil activation. The mechanism of action (MOA) of the IL-5/ IL-5R receptor antagonists works by blocking the interaction between IL-5 and its receptor. By inhibiting this interaction, these drugs interfere with the signaling pathway that promotes eosinophil production, maturation, activation, and survival. This leads to a reduction in the number and activity of eosinophils in the body. IL-5/IL-5R antagonists act to downregulate eosinophil activity and provide therapeutic benefits in diseases characterized by excessive eosinophilic inflammation, such as eosinophilic asthma and eosinophilic esophagitis. IL-5/ IL-5R antagonist drugs can help alleviate symptoms, reduce exacerbations, and improve overall disease control. IL-5/ IL-5R antagonists are used to treat asthma, respiratory hypersensitivity, bronchial diseases, lung diseases, nose diseases, allergic rhinitis, brain diseases, common cold, gastroenteritis, autoimmune diseases, and lymphatic diseases. Increased incidence of respiratory tract infections and allergic rhinitis are the key drivers for the IL-5/ IL-5R market.

For instance, according to the Centers for Disease Control and Prevention 2021, around there were 4.6% of adults who have ever been diagnosed with COPD, emphysema, or chronic bronchitis. The introduction of newer products by market players may look for opportunities that greatly impact comprehensive research and development in IL-5/ IL-5R antagonists. For instance, GlaxoSmithKline launched Nucala (Mepolizumab) to treat chronic rhinosinusitis. Moreover, numerous market participants are developing innovative compounds to address the difficulties in therapy. For instance, GSK’s Depemokimab (GSK3511294) for the indication of asthma is under the various stages of clinical studies.

Key Market Developments:

  • In September 2020, GlaxoSmithKline received an FDA grant for an expanded indication of its Nucala (Mepolizumab) for Hypereosinophilic Syndrome.
  • In July 2021, GlaxoSmithKline received an FDA grant for an expanded indication of its Nucala (Mepolizumab) for chronic rhinosinusitis with nasal polyps.

Approved Drug Molecules and Brand Names for IL-5/ IL-5R Antagonists Drugs:

  • Nucala (Mepolizumab)
  • Cinqair (Reslizumab)
  • Fasenra (Benralizumab)

Drugs under the Pipeline for IL-5/ IL-5R Antagonists Drugs:

  • Orismilast Oral (LEO 32731)
  • Depemokimab (GSK3511294)
  • ASM8
  • SHR-1703
  • SSGJ-610
  • BAT2606 (Mepolizumab Biosimilar)
  • Mepolizumab Biosimilar
  • Orismilast Topical (LEO 32731 Topical)
  • Trabikibart (CSL311)

Clinical Activity and Developments of IL-5/ IL-5R Antagonists Drugs:

Till July 2023, there will be about 12 companies with over 15 compounds that focus on various forms of respiratory and hypersensitivity disorders. For these molecules, more than 270 clinical trials are being conducted, and most are in phase-2 and phase-3 clinical trials by players across the globe. For instance,

  • In October 2019, AstraZeneca received the FDA for the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen) based on the data from the Phase III GRECO trial and the Phase I AMES trial.
  • In May 2023, Innovent Biologics completed phase 1, a randomized, double-blind, placebo-controlled, multiple oral dose trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic of IBI353 (Orismilast) in healthy subjects.

Molecule  Name

Number of Studies

Orismilast Oral (LEO 32731)

12

Depemokimab (GSK3511294)

11

ASM8

6

SHR-1703

4

SSGJ-610

3

Target Indication Analysis of IL-5/ IL-5R Antagonists Drugs

GlaxoSmithKline developed molecules such as Nucala (Mepolizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype, adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause, and chronic rhinosinusitis with nasal polyps. Moreover, Teva Pharmaceuticals Nucala (Mepolizumab) is specifically indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

Nucala (Mepolizumab), Cinqair (Reslizumab), Fasenra (Benralizumab), etc are the few FDA approved IL-5/ IL-5R.

Total sales of GSK’s Nucala (Mepolizumab) were US$751 million in FY2018 globally.

GSK, AstraZeneca, Merck (MSD), UCB, Teva are a few leading market players in IL-5/ IL-5R Market.

asthma, respiratory hypersensitivity, bronchial diseases, lung diseases, nose diseases, allergic rhinitis, brain diseases, common cold, gastroenteritis, autoimmune diseases, etc are the major indication of IL-5/ IL-5R antagonist.

There are a total of nine molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  • GSK
  • AstraZeneca
  • Merck (MSD)
  • UCB
  • Teva
  • UNION Therap
  • Pharmaxis
  • Jiangsu Hengrui Pharma
  • 3SBio
  • Bio-Thera Solutions
  • Sino Biopharm
  • CSL Behring

Related Industry Reports